Arix Bioscience PLC

Arix Bioscience’s investee company Aura Biosciences announces positive data from mid-stage eye cancer trial

The data from a phase Ib/II trial of Aura’s AU-011 eye cancer treatment show the injection doesn’t do too much damage to the surrounding healthy tissue in patients’ eyes

Ocular melanoma is the most common type of eye cancer

Arix Bioscience Plc’s (LON:ARIX) investee company Aura Biosciences has reported positive results from the phase Ib/II clinical trial of its AU-011 eye cancer injection.

AU-011 is made up of viral nanoparticles which latch onto and, once activated by an ophthalmic laser, kill cancer cells in the back of the eye.

READ: Arix boosted by LogicBio's Nasdaq IPO

Importantly, they do this without damaging the surrounding tissue, preserving patients’ vision.

Brian Marr, the trial’s principal investigator, said: “These 12-month data demonstrate that light-activated AU-011 continues to be well-tolerated, including with multiple administrations, has evidence of tumour control and preservation of visual acuity”

Arix chief investment officer Joe Anderson added: “We believe that this minimally invasive, non-radiation-based treatment option, has the potential to offer a new treatment option for patients.”

“We continue to support Aura as the company progresses towards a pivotal phase III study.”

Arix, which has a 6.6% stake in Aura, saw its shares drop 4.1% to 162.6p in late-afternoon trading.

Quick facts: Arix Bioscience PLC

Price: £1.12

Market: LSE
Market Cap: £151.14 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Arix Bioscience PLC named herein, including the promotion by the Company of Arix Bioscience PLC in any Content on the Site, the Company...



Arix Bioscience acquires stake in novel firm developing sickle cell treatment

Arix Bioscience PLC (LON:ARIX) investment associate John Cassidy talks Proactive London through its decision to invest US$15mln (£11.3mln) in Imara - a firm which is developing treatments for sickle cell disease. Through the deal Arix receives a 10% stake in the company while also...

on 19/3/19

2 min read